Our current clinical projects

Proprietary projects

Project & Mechanism
Disease areas
Research
Preclinical
Phase I
Phase II
Phase III
Market

MIV-818

Nucleotide DNA polymerase inhibitor (oral)

Hepatocellular carcinoma

MIV-828

Treatment of blood cancer (intravenous)

Blood cancer (acute myeloid leukemia)

Projects for licensing

Project & Mechanism
Disease areas
Research
Preclinical
Phase I
Phase II
Phase III
Market

Remetinostat

HDAC inhibitor (topical)

Cutaneous T-cell lymphoma (MF)

Basal cell carcinoma1)

Squamous cell carcinoma1)

Birinapant

SMAC mimetic (intravenous)

Head & Neck cancer (with radiation)2)

MIV-711

Cathepsin K inhibitor (oral)

Osteoarthritis

1) Investigator sponsored study at Stanford U.

2) Investigator sponsored study at NCI, USA.

Outlicensed projects

Project & Mechanism
Disease areas
Research
Preclinical
Phase I
Phase II
Phase III
Market

Xerclear® (Zoviduo®)

Hydrocortisone and aciclovir combination

Labial herpes

MIV-802

Nucleotide NS5B polymerase inhibitor

Hepatitis C

Our current clinical projects

Proprietary

MIV-818

Nucleotide DNA polymerase inhibitor (oral)

  • Mechanism

    Nucleotide DNA polymerase inhibitor (oral)

  • Disease area

    Hepatocellular carcinoma

    Phase I

MIV-828

Treatment of blood cancer (intravenous)

  • Mechanism

    Nucleotide DNA Polymerase inhibitor (intravenous)

  • Disease area

    Blood cancer (acute myeloid leukemia)

    Research

Partnerships

Xerclear® (Zoviduo®)

Hydrocortisone and aciclovir combination

  • Mechanism

    Hydrocortisone and aciclovir combination

  • Disease area

    Labial herpes

    Market

MIV-802

Nucleotide NS5B polymerase inhibitor

  • Mechanism

    Nucleotide NS5B polymerase inhibitor

  • Disease area

    Hepatitis C

    Preclinical